Qiagen N.V. $QGEN Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC reduced its position in Qiagen N.V. (NYSE:QGEN) by 24.1% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 144,789 shares of the company’s stock after selling 45,949 shares during the period. Segall Bryant & Hamill LLC’s holdings in Qiagen were worth $6,469,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. United Services Automobile Association purchased a new position in Qiagen during the first quarter worth about $239,000. Envestnet Asset Management Inc. boosted its holdings in Qiagen by 26.6% in the second quarter. Envestnet Asset Management Inc. now owns 425,396 shares of the company’s stock valued at $20,439,000 after acquiring an additional 89,301 shares during the last quarter. Atria Investments Inc grew its position in Qiagen by 2.9% during the second quarter. Atria Investments Inc now owns 7,674 shares of the company’s stock valued at $369,000 after acquiring an additional 218 shares during the period. Amalgamated Bank grew its position in Qiagen by 1.8% during the second quarter. Amalgamated Bank now owns 11,751 shares of the company’s stock valued at $565,000 after acquiring an additional 209 shares during the period. Finally, Simon Quick Advisors LLC acquired a new stake in Qiagen during the second quarter worth about $208,000. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

QGEN has been the topic of a number of recent research reports. JPMorgan Chase & Co. lifted their price target on shares of Qiagen from $55.00 to $60.00 and gave the company an “overweight” rating in a research report on Friday, February 6th. Wall Street Zen raised Qiagen from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Weiss Ratings restated a “hold (c)” rating on shares of Qiagen in a report on Monday, December 29th. Stifel Nicolaus set a $50.00 price objective on shares of Qiagen and gave the company a “hold” rating in a research report on Friday, February 6th. Finally, UBS Group set a $52.00 price objective on shares of Qiagen in a research note on Monday, February 9th. Four analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $55.20.

Qiagen Trading Down 1.8%

Shares of QGEN opened at $46.81 on Thursday. The company has a market capitalization of $9.88 billion, a P/E ratio of 23.21, a P/E/G ratio of 2.32 and a beta of 0.70. Qiagen N.V. has a one year low of $39.92 and a one year high of $57.81. The company has a debt-to-equity ratio of 0.44, a quick ratio of 3.31 and a current ratio of 3.90. The stock has a 50-day moving average price of $49.98 and a 200 day moving average price of $49.27.

Qiagen (NYSE:QGEN) last posted its quarterly earnings data on Thursday, February 5th. The company reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.61 by $0.01. Qiagen had a return on equity of 14.56% and a net margin of 20.33%.The company had revenue of $540.42 million for the quarter, compared to the consensus estimate of $528.53 million. During the same period in the previous year, the business earned $0.61 EPS. Qiagen’s revenue for the quarter was up 3.6% compared to the same quarter last year. Sell-side analysts forecast that Qiagen N.V. will post 2.26 EPS for the current fiscal year.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.